Fluorescent PLGA-Rhodamine from PolySciTech used in the development of inhalable, antimicrobial nanoparticles

 

Antimicrobial resistance creates a significant barrier to treatment of bacterial infection. SET-M33, a non-natural antimicrobial peptide, can be used for treatment of cystic fibrosis however requires a delivery mechanism to provide it to the appropriate location in the lung tissue. Recently researchers at University of Siena, SetLance srl, University of Campania, and University of Naples used PLGA-Rhodamine (Cat # AV011) from PolySciTech division of Akina, Inc. (www.polyscitech.com) in development of an SET-M33 delivery nanoparticle. This research holds promise to improve treatment of lung-bacterial infections. Read more: Cresti, Laura, Gemma Conte, Giovanni Cappello, Jlenia Brunetti, Chiara Falciani, Luisa Bracci, Fabiana Quaglia, Francesca Ungaro, Ivana d’Angelo, and Alessandro Pini. "Inhalable Polymeric Nanoparticles for Pulmonary Delivery of Antimicrobial Peptide SET-M33: Antibacterial Activity and Toxicity In Vitro and In Vivo." Pharmaceutics 15, no. 1 (2023): 3. https://www.mdpi.com/2017528

“Abstract: Development of inhalable formulations for delivering peptides to the conductive airways and shielding their interactions with airway barriers, thus enhancing peptide/bacteria interactions, is an important part of peptide-based drug development for lung applications. Here, we report the construction of a biocompatible nanosystem where the antimicrobial peptide SET-M33 is encapsulated within polymeric nanoparticles of poly(lactide-co-glycolide) (PLGA) conjugated with polyethylene glycol (PEG). This system was conceived for better delivery of the peptide to the lungs by aerosol. The encapsulated peptide showed prolonged antibacterial activity, due to its controlled release, and much lower toxicity than the free molecule. The peptide-based nanosystem killed Pseudomonas aeruginosa in planktonic and sessile forms in a dose-dependent manner, remaining active up to 72 h after application. The encapsulated peptide showed no cytotoxicity when incubated with human bronchial epithelial cells from healthy individuals and from cystic fibrosis patients, unlike the free peptide, which showed an EC50 of about 22 µM. In vivo acute toxicity studies in experimental animals showed that the peptide nanosystem did not cause any appreciable side effects, and confirmed its ability to mitigate the toxic and lethal effects of free SET-M33. Keywords: polymeric nanoparticles; lung delivery; inhalable formulations; nanoparticle properties; aerosolization; nanoparticle/mucus interactions; antimicrobial peptides; antimicrobial resistance; Pseudomonas aeruginosa”



Video: https://youtu.be/looWDKpAwFY